Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm ....
Transcript of Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm ....
![Page 1: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/1.jpg)
Dianas terapeúticas: ser o no ser, esa es la cuestión En Oncología
Miquel Àngel Seguí Palmer
![Page 2: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/2.jpg)
Dianas terapeúticas en Oncología
TIMER
Targeted therapy involves developing drugs that block cancer cell proliferation, promote cell cycle regulation or induce apoptosis or autophagy and targeted delivery of toxic substances specifically to cancer cells to destroy them. Targeted therapy involves the use of monoclonal antibodies or oral small drugs
![Page 3: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/3.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 4: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/4.jpg)
Dianas terapeúticas en Oncología
TIMER
Two images of a Breast Cancer
The standard paradigm of classifying patients by histology alone, and treating large unselected groups of patients with the same treatment is unlikely to dramatically improve outcomes.
A different approach entails matching molecular classification with targeted therapy.
![Page 5: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/5.jpg)
Dianas terapeúticas en Oncología
TIMER
The shift of paradigm: towards molecular subsets of cancers
![Page 6: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/6.jpg)
Dianas terapeúticas en Oncología
TIMER
The shift of paradigm: molecular alterations shared in several cancers
![Page 7: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/7.jpg)
Dianas terapeúticas en Oncología
TIMER
Expression profile Identification of Breast Tumor Intrinsic Subtypes
Carey, L. A. et al. JAMA 2006;295:2492-2502
The challenge that arises from the molecular subclassification of malignancies is that molecularly distinct cancer subtypes may each become orphan diseases.
![Page 8: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/8.jpg)
Dianas terapeúticas en Oncología
TIMER
Targeted therapy aims at delivering drugs to particular genes or proteins that are specific to cancer cells or the tissue environment that promotes cancer growth.
![Page 9: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/9.jpg)
Dianas terapeúticas en Oncología
TIMER
Traditional cytotoxic chemotherapy works primarily through the inhibition of cell division
Targeted therapy blocks the proliferation of cancer cells by interfering with specific molecules required for tumor development and growth
![Page 10: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/10.jpg)
Dianas terapeúticas en Oncología
TIMER
Targeted therapies vs. standard chemotherapy
![Page 11: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/11.jpg)
Dianas terapeúticas en Oncología
TIMER
Targeted therapies differ from standard chemotherapy in several ways:
• Targeted therapies act on specific molecular targets that
are associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells.
• Targeted therapies are deliberately chosen or designed to interact with their target, whereas many standard chemotherapies were identified because they kill cells.
• Targeted therapies are often cytostatic (that is, they block tumor cell proliferation), whereas standard chemotherapy agents are cytotoxic (that is, they kill tumor cells).
![Page 12: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/12.jpg)
Dianas terapeúticas en Oncología
TIMER
Unlike traditional cytotoxic chemotherapies that have frequently entered the clinic without exact knowledge of their mechanism of action and have been discovered and developed on the basis of their ability to interfere with cell division, molecularly designed drugs, on the other hand, have been developed based on a particular known molecular target. Thus, a primary goal of molecularly targeted cancer therapies is to fight cancer with more precision than traditional chemotherapy regimens and hopefully with the additional benefit of less adverse side effects for the patient in treatment.
![Page 13: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/13.jpg)
Dianas terapeúticas en Oncología
TIMER
Myth: Targeted therapy is new (or what were we thinking?)
• DNA is not a bad target.
• Tubulin is a very good target.
• Specific receptor targeting: tamoxifen etc.
![Page 14: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/14.jpg)
Dianas terapeúticas en Oncología
TIMER
• A superficial definition of targeted therapy implies that it is a therapy that is used to target a specific molecular aberration or genetic anomaly. The targeting of HER2 overexpression with the monoclonal antibody, trastuzumab is a example of targeted treatment .
• By contrast, we could use bevacizumab as an example, hailed as an agent that targets VEGF-A. To date, however, we have been unable to identify biomarkers that can be used to select a population primed for therapeutic response to anti-VEGF therapy.
• Finally, a given ‘targeted’ therapeutic agent might impact multiple targets (for example, sorafenib, which is a multikinase inhibitor) instead of a single one. Hence, targeted therapy cannot always be defined as having single-target specificity.
![Page 15: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/15.jpg)
Dianas terapeúticas en Oncología
TIMER
(1) angiogenic blood vessels (e.g. Bevacuzimab) (2) re-education of the immune system (e.g. Ipilimumab), (3) extracellular domains of transmembrane receptors (e.g. Cetuximab and Trastuzumab) (4) intracellular targets, such as TK domains and downstream signaling (e.g. Imatinib). (5 &6) nuclear signaling (e.g. SERMs).
Røsland GV, Engelsen AS. Basic Clin Pharmacol Toxicol. 2015;116(1):9-18
![Page 16: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/16.jpg)
Dianas terapeúticas en Oncología
TIMER
What types of targeted therapies are available?
• Hormone therapies
• Signal transduction inhibitors
• Gene expression modulators
• Apoptosis inducers
• Angiogenesis inhibitors
• Immunotherapies
• Monoclonal antibodies that deliver toxic molecules
![Page 17: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/17.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 18: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/18.jpg)
Dianas terapeúticas en Oncología
TIMER
Targeted therapies in breast cancer
![Page 19: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/19.jpg)
Dianas terapeúticas en Oncología
TIMER
Targeted therapies in non-small cell lung cancer
![Page 20: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/20.jpg)
Dianas terapeúticas en Oncología
TIMER
Adjuvant Trastuzumab in Her2+ Breast Cancer
Crizotinib in ALK+ metastatic NSCLC
![Page 21: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/21.jpg)
Dianas terapeúticas en Oncología
TIMER
Erlotinib in Advanced Pancreatic Cancer
Bevacizumab in metastatic Breast cancer
![Page 22: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/22.jpg)
Dianas terapeúticas en Oncología
TIMER
The Increasing Precision on Anticancer Therapeutics
![Page 23: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/23.jpg)
Dianas terapeúticas en Oncología
TIMER
Limitations of Targeted Therapies
• Tumor Heterogeneity
• Molecular Evolution and Resistance
• Undruggable Targets
• Technical Challenges
• Need for New Trial Designs
• Pharmacological Challenges
![Page 24: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/24.jpg)
Dianas terapeúticas en Oncología
TIMER
Targetable genomic alterations in breast cancer
![Page 25: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/25.jpg)
Dianas terapeúticas en Oncología
TIMER
It should be noted that side effects of some molecularly targeted drugs are not insignificant, and neither are the treatment costs, highlighting the importance of identifying reliable biomarkers to predict which patients will benefit from a particular treatment.
![Page 26: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/26.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 27: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/27.jpg)
Dianas terapeúticas en Oncología
TIMER
Over 20 tumor types are being treated with new medicines that have been launched in the past five years
![Page 28: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/28.jpg)
Dianas terapeúticas en Oncología
TIMER
Growth of the Late Phase Oncology Pipeline, 2005-2015
![Page 29: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/29.jpg)
Dianas terapeúticas en Oncología
TIMER
Patients in only 6 countries had access to at least half of the 49 new oncology medicines launched 2010-2014
![Page 30: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/30.jpg)
Dianas terapeúticas en Oncología
TIMER
Shifting the Paradigm
![Page 31: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/31.jpg)
Dianas terapeúticas en Oncología
TIMER
THERAPEUTIC TARGETING OF THE HALLMARKS OF CANCER
![Page 32: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/32.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 33: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/33.jpg)
Dianas terapeúticas en Oncología
TIMER
“Doctors have always recognized that every patient is unique, and doctors have always tried to tailor their treatments as best they can to individuals.
What if matching a cancer cure to our genetic code was just as easy, just as standard?
What if figuring out the right dose of medicine was as simple as taking our temperature?”
Precision Medicine
![Page 34: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/34.jpg)
Dianas terapeúticas en Oncología
TIMER
The use of an individual patient’s molecular information (including genomics and proteomics) to inform diagnosis, prognosis, treatment and prevention of cancer for that patient.
Precision Medicine
![Page 35: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/35.jpg)
Dianas terapeúticas en Oncología
TIMER
Precision Medicine
![Page 36: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/36.jpg)
Dianas terapeúticas en Oncología
TIMER
“The right patient, the right disease, the right drug”
![Page 37: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/37.jpg)
Dianas terapeúticas en Oncología
TIMER
Oncology is at the frontline of personalised medicine, moving beyond the previous model of giving cancer therapeutics based on trials of largely unselected patients beyond a simple phenotypic marker, to leading the way in utilising the molecular profile of an individual’s cancer genome to optimise their disease management.
![Page 38: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/38.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 39: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/39.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 40: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/40.jpg)
Dianas terapeúticas en Oncología
TIMER
Novel clinical trial designs to test precision-medicine approaches in cancer
![Page 41: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/41.jpg)
Dianas terapeúticas en Oncología
TIMER
Matching Each Cancer with Individually Targeted Therapy
![Page 42: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/42.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 43: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/43.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 44: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/44.jpg)
Dianas terapeúticas en Oncología
TIMER
A small subset of cancer patients with actionable mutations could be expected to benefit from targeted therapy with either commercially available drugs or drugs in clinical trials. Although the response rate to targeted therapy could be improved based on personalized biomarker selection, there remain many driver mutations for which effective targeted drugs are not available.
![Page 45: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/45.jpg)
Dianas terapeúticas en Oncología
TIMER
• Driving somatic genetic mutations causing cancer development/progression are the scientific basis of the development of molecularly targeted drugs.
• Targeted therapies, which include monoclonal antibodies and small molecule inhibitors, have significantly changed the treatment of cancer over the past 10 years.
• The mechanisms of action and toxicities of targeted therapies differ from those of traditional cytotoxic chemotherapy. Targeted therapies are generally better tolerated than traditional chemotherapy, but they are associated with several adverse effects.
Take-home messages…...(1)
![Page 46: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/46.jpg)
Dianas terapeúticas en Oncología
TIMER
• Molecular genetics converts severe frequent cancers into specific rare cancers with specific treatment. The selection of patients for targeted therapy remains a challenge because we lack reliable biomarkers to predict activity for most of the targeted agents.
• Traditional methodologies applied for drug development are likely inappropriate for new targeted agents.
• Targeted therapy has raised new questions about the tailoring of cancer treatment to an individual patient’s tumor, the assessment of drug effectiveness and toxicity, and the economics of cancer care.
• Personalised medicine, will lead the way in utilising the molecular profile of an individual’s cancer genome to optimise their disease management.
Take-home messages…...(2)
![Page 47: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/47.jpg)
Dianas terapeúticas en Oncología
TIMER
![Page 48: Dianas terapeúticas: ser o no ser, esa es la cuestión En ...€¦ · Shifting the Paradigm . Dianas terapeúticas en Oncología TIMER ... genomics and proteomics) to inform diagnosis,](https://reader033.fdocuments.us/reader033/viewer/2022043004/5f8907bd43d50e545f48ab9d/html5/thumbnails/48.jpg)